Nasus Pharma is trading 5.6% down at $3.87, based on the provided live price; no company announcement dated August 26, 2026, or source-confirmed catalyst directly explaining the decline was found.
- The latest official update, published August 17, reported first-half results and a $5.9 million net loss.
- Cash was expected to fund operations through Q2 2027.
- Broader indexes were nearly flat to modestly lower, offering limited explanation.